1
|
Adler LA, Anbarasan D, Sardoff T, Leon T, Gallagher R, Massimi CA, Faraone SV. A Single-Blind, Placebo Controlled Trial of Triple Beaded Mixed Amphetamine Salts in DSM-5 Adults With ADHD Assessing Effects Throughout the Day. J Atten Disord 2024; 28:810-819. [PMID: 38214178 DOI: 10.1177/10870547231222260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2024]
Abstract
OBJECTIVE To examine the effects of triple beaded mixed amphetamine salts (TB MAS) on ADHD and executive dysfunction symptoms throughout the day in adults with DSM-5 ADHD. METHOD This was a 6 week, single-blind, placebo-lead in trial of TB MAS (12.5-37.5 mg/day); all participants received 2 weeks of single-blind placebo); one individual was a placebo responder and was discontinued. One of these 18 dropped after 1 week on 12.5 mg/day, while all others completed the trial and received 37.5 mg/day TB MAS. RESULTS There were significant effects of TB MAS on all clinical measures, including investigator overall symptoms (AISRS); self-report overall (ASRS), time-sensitive ADHD (TASS) scores throughout the day, impairment (CGI) and executive function scores (BRIEF-A). TB MAS was generally well tolerated. CONCLUSIONS This study extends prior findings of TB MAS to adults with DSM-5 ADHD; it further re-validates findings of efficacy of TB MAS throughout the day.
Collapse
|
2
|
Adler LA, Anbarasan D, Leon T, Sardoff T, Descorbeth O, Cho D, Stern Y, Kraft O, Hendler T, Marmar CR. Pilot Study of Prism EFP NeuroFeedback in Adult ADHD. J Atten Disord 2024; 28:905-912. [PMID: 38152997 DOI: 10.1177/10870547231215283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2023]
Abstract
OBJECTIVE A pilot study to preliminarily examine the effects of Prism EFP NeuroFeedback (NF) in adult ADHD. METHOD Prism EFP NF is a form of NF specifically designed to target emotional dysregulation (ED) through down regulation of amygdala activity. Prism EFP NF has been shown to improve other disorders with significant ED. Nine participants with adult ADHD received an open trial of Prism EFP NF consisting of fifteen sessions over 8 weeks; all completed at least 5 weeks of treatment with seven completing all 8 weeks. Outcomes were assessed by change in ADHD symptoms from baseline to End of Treatment. RESULTS About two-third reduction was seen in total DSM ADHD symptom scores (primary outcome measure) with improvement observed in all other clinical measures. No significant adverse events were seen. CONCLUSION This preliminary trial found substantial effects of Prism EFP NF on ADHD/ED symptoms and global impairment.
Collapse
Affiliation(s)
| | | | - Terry Leon
- NYU Grossman School of Medicine, New York, NY, USA
| | | | | | - Dayeon Cho
- NYU Grossman School of Medicine, New York, NY, USA
| | | | | | - Talma Hendler
- GrayMatters Health, Haifa, Israel
- Tel Aviv University, Israel
| | | |
Collapse
|
3
|
Diaz M, Reyes S, Adur A, Cuartero V, Leon T, Raffa I, Sanchez P, Dioca M. P-7 Induction chemotherapy in locally advanced rectal cancer: Retrospective report of efficacy and safety in an Argentinean university institution, a feasibility perspective. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
4
|
Li Z, Abraham BJ, Berezovskaya A, Farah N, Liu Y, Leon T, Fielding A, Tan SH, Sanda T, Weintraub AS, Li B, Shen S, Zhang J, Mansour MR, Young RA, Look AT. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia 2017; 31:2057-2064. [PMID: 28260788 PMCID: PMC5629363 DOI: 10.1038/leu.2017.75] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Revised: 01/27/2017] [Accepted: 02/24/2017] [Indexed: 12/16/2022]
Abstract
Oncogenic driver mutations are those that provide a proliferative or survival advantage to neoplastic cells, resulting in clonal selection. Although most cancer-causing mutations have been detected in the protein-coding regions of the cancer genome; driver mutations have recently also been discovered within noncoding genomic sequences. Thus, a current challenge is to gain precise understanding of how these unique genomic elements function in cancer pathogenesis, while clarifying mechanisms of gene regulation and identifying new targets for therapeutic intervention. Here we report a C-to-T single nucleotide transition that occurs as a somatic mutation in noncoding sequences 4 kb upstream of the transcriptional start site of the LMO1 oncogene in primary samples from patients with T-cell acute lymphoblastic leukaemia. This single nucleotide alteration conforms to an APOBEC-like cytidine deaminase mutational signature, and generates a new binding site for the MYB transcription factor, leading to the formation of an aberrant transcriptional enhancer complex that drives high levels of expression of the LMO1 oncogene. Since APOBEC-signature mutations are common in a broad spectrum of human cancers, we suggest that noncoding nucleotide transitions such as the one described here may activate potent oncogenic enhancers not only in T-lymphoid cells but in other cell lineages as well.
Collapse
Affiliation(s)
- Z Li
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - B J Abraham
- Whitehead Institute for Biomedical Research, Cambridge, MA, USA
| | - A Berezovskaya
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - N Farah
- Department of Haematology, UCL Cancer Institute, University College London, London, UK
| | - Y Liu
- Department of Computational Biology, St Jude Children’s Research Hospital, Memphis, TN, USA
| | - T Leon
- Department of Haematology, UCL Cancer Institute, University College London, London, UK
| | - A Fielding
- Department of Haematology, UCL Cancer Institute, University College London, London, UK
| | - S H Tan
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
- Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore
| | - T Sanda
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
- Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore
| | - A S Weintraub
- Whitehead Institute for Biomedical Research, Cambridge, MA, USA
| | - B Li
- Department of Hematology and Oncology, Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Pediatric Translational Medicine Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - S Shen
- Department of Hematology and Oncology, Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Pediatric Translational Medicine Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - J Zhang
- Department of Computational Biology, St Jude Children’s Research Hospital, Memphis, TN, USA
| | - M R Mansour
- Department of Haematology, UCL Cancer Institute, University College London, London, UK
| | - R A Young
- Whitehead Institute for Biomedical Research, Cambridge, MA, USA
- Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - A T Look
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Division of Hematology/Oncology, Children’s Hospital, Boston, MA, USA
| |
Collapse
|
5
|
Adler LA, Alperin S, Leon T, Faraone SV. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2017; 27:196-199. [PMID: 27935735 DOI: 10.1089/cap.2016.0121] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND Lisdexamfetamine (LDX) is a prodrug and consists of an active moiety, d-amphetamine, bound to lysine. Clinically, d-amphetamine becomes available postcleavage of the prodrug in the blood stream. Clinical effects of LDX in attention-deficit/hyperactivity disorder (ADHD) have been shown to persist up to 14 hours; however, pharmacokinetic (PK) data of LDX and amphetamine in ADHD adults are not currently available. OBJECTIVES (1) To examine PK data of LDX and d-amphetamine in plasma and (2) to compare such PK data with Time-Sensitive ADHD Symptom Scale (TASS) ratings (PK vs. pharmacodynamic [PD]). METHODS Plasma d-amphetamine/LDX levels and TASS ratings were obtained immediately before morning dosing and then 0.5, 1, 2, 4, 6, 8, 10, and 12 hours postdosing in 21 adults with ADHD treated with 5 weeks of single-blind LDX up to 70 mg/day (after 1 week single-blind placebo). ADHD Rating Scale scores were obtained at the beginning of the visit, before morning dosing. RESULTS LDX levels peaked at 1.5 hours after administration (Tmax) and then rapidly declined (levels were negligible at 6 hours and area under the plasma concentration versus time curve, AUC = 45.9, Cmax = 25.0, and half-life [t1/2] = 0.5 hours). Levels of d-amphetamine peaked at (Tmax) 4.4 hours and then slowly declined (AUC = 641.6, Cmax = 67.9, and t1/2 = 17.0 hours). No statistically significant correlations were seen between d-amphetamine levels and TASS scores. CONCLUSIONS (1) Prodrug LDX levels peaked fairly rapidly and declined, while d-amphetamine levels peaked 3 hours later than LDX levels and persisted throughout the day and (2) the absence of PK/PD correlations between PK data and TASS ratings may be due to the subjects being tested in a controlled nonattention demanding environment.
Collapse
Affiliation(s)
- Lenard A Adler
- 1 Department of Psychiatry, NYU Langone School of Medicine , New York, New York
| | - Samuel Alperin
- 1 Department of Psychiatry, NYU Langone School of Medicine , New York, New York.,2 Hofstra Northwell School of Medicine, Hofstra University , Hempstead, New York
| | - Terry Leon
- 1 Department of Psychiatry, NYU Langone School of Medicine , New York, New York
| | - Stephen V Faraone
- 3 Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University , Syracuse, New York
| |
Collapse
|
6
|
Yang Z, Kelly C, Castellanos FX, Leon T, Milham MP, Adler LA. Neural Correlates of Symptom Improvement Following Stimulant Treatment in Adults with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2016; 26:527-36. [PMID: 27027541 PMCID: PMC4991601 DOI: 10.1089/cap.2015.0243] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
OBJECTIVE The purposes of this study were to examine the impact of 3 weeks of amphetamine administration on intrinsic connectome-wide connectivity patterns in adults with attention-deficit/hyperactivity disorder (ADHD) and explore the association between stimulant-induced symptom improvement and functional connectivity alteration. METHODS Participants included 19 adults (age 20-55 years) diagnosed with ADHD using the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria per the Adult Clinician Diagnostic Scale taking part in amphetamine trials. For each patient, two 6-minute resting-state functional magnetic resonance imaging (R-fMRI) scans were acquired at baseline and after treatment. A fully data-driven multivariate analytic approach (i.e., multivariate distance matrix regression [MDMR]) was applied to R-fMRI data to characterize the distributed pharmacological effects in the entire functional connectome. Clinical efficacy was assessed using ADHD rating scale with adult prompts and the Adult Self-Report Scale v1.1 Symptom Checklist. We linked stimulant-induced functional connectivity changes to symptom amelioration using Spearman's correlation. RESULTS Three weeks of administration of a stimulant significantly reduced ADHD symptoms. MDMR-based analyses on R-fMRI data highlighted the left dorsolateral prefrontal cortex (DLPFC, a key cognitive control region) and the medial prefrontal cortex (MPFC, the anterior core of default network) whose distributed patterns of functional connectivity across the entire brain were altered by psychostimulants. Follow-up intrinsic functional connectivity revealed that stimulants specifically decreased the positive functional connectivity between DLPFC-insula, DLPFC-anterior cingulate cortex, and MPFC-insula. Importantly, these functional connectivity changes are associated with symptom improvement. CONCLUSION These results suggested that ADHD is associated with increased functional integration or decreased functional segregation between core regions of cognitive control, default, and salience networks. The apparent normalization of intrinsic functional interaction in these circuits (i.e., increased functional segregation) may underlie the clinical benefits produced by 3 weeks of amphetamine treatment.
Collapse
Affiliation(s)
- Zhen Yang
- Center for the Developing Brain, Child Mind Institute, New York, New York.,Nathan Kline Institute for Psychiatric Research, Orangeburg, New York
| | - Clare Kelly
- The Child Study Center at NYU Langone Medical Center, New York, New York
| | - Francisco X. Castellanos
- Nathan Kline Institute for Psychiatric Research, Orangeburg, New York.,The Child Study Center at NYU Langone Medical Center, New York, New York
| | - Terry Leon
- Department of Psychiatry, NYU Langone School of Medicine, New York, New York
| | - Michael P. Milham
- Center for the Developing Brain, Child Mind Institute, New York, New York.,Nathan Kline Institute for Psychiatric Research, Orangeburg, New York
| | - Lenard A. Adler
- Department of Psychiatry, NYU Langone School of Medicine, New York, New York
| |
Collapse
|
7
|
Gage M, Pourcet B, Leon T, Valledor A, Pineda-Torra I. Multiple novel regulatory mechanisms of IL-18 by the lipid-activated nuclear receptor LXR. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Adler LA, Alperin S, Leon T, Faraone S. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial. Postgrad Med 2014; 126:17-24. [PMID: 25295646 DOI: 10.3810/pgm.2014.09.2796] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVES To examine the clinical effects of equivalent doses of single-blind (SB; patient-blind) lisdexamfetamine (LDX) and mixed amphetamine salts-immediate release (MAS-IR) on adult attention-deficit/hyperactivity disorder (ADHD) in a placebo (PBO)-controlled, crossover design. METHODS Twenty-four subjects were treated sequentially in a fixed order with (1) SB PBO (matching LDX) for 1 week, (2) SB LDX (up to 70 mg/day) for 5 weeks, (3) SB PBO washout for 3 weeks, and (4) open-label treatment MAS-IR (tid up to 45 mg/day) for 5 weeks. Clinical effects on ADHD and executive function were assessed weekly throughout the trial with the ADHD Rating Scale with adult prompts, the Clinical Global Impression Severity Scale (CGI-S), and the Behavior Rating Inventory of Executive Function (BRIEF). RESULTS Lisdexamfetamine and MAS-IR were generally well tolerated. Significant and equal reductions on ADHD clinician ratings were seen. Significantly greater reductions in CGI-S and selected BRIEF subsets were observed in LDX over MAS-IR treatment. However, in general, baseline scores for MAS-IR treatment did not fully return to the LDX baseline. Adherence in this structured and monitored clinical trial was good for once daily LDX and 3 times a day MAS-IR. CONCLUSIONS In this crossover study, both LDX and MAS-IR had significant effects on ADHD clinician ratings and measures of executive function (with response rates of about 80%); patients in this monitored clinical trial were adherent with once daily LDX and 3 times a day MAS-IR, which may not be the case in real-world clinical practice. The findings of some superiority of LDX over MAS-IR on the CGI-S and BRIEF ratings may be influenced by the variability in the baselines used, but nevertheless should be further investigated in larger scale, parallel-design clinical trials.
Collapse
Affiliation(s)
- Lenard A Adler
- Departments of Psychiatry and Child and Adolescent Psychiatry, New York University School of Medicine, New York, NY
| | | | | | | |
Collapse
|
9
|
Abstract
Neuropsychiatric manifestations are serious and frequent complications of systemic lupus erythematous (SLE). Catatonia is a neuropsychiatric disorder characterized by motor disturbance (including waxy flexibility and catalepsy), stupor, excitement, negativism, mutism, echopraxia and echolalia. Catatonia associated with SLE has been only rarely reported, especially in children. Here we present a case of a 14-year-old patient encountered in consultation-liaison psychiatry who presented catatonia associated with SLE. Her catatonia was refractory to treatment with pulse methylprednisolone, intravenous cyclophosphamide and rituximab. The patient responded to a combined therapy of electroconvulsive therapy and benzodiazepines. The present case suggests that although rarely reported, catatonia seen in the background of SLE should be promptly identified and treated to reduce the morbidity.
Collapse
Affiliation(s)
- T Leon
- Section of Consultation-Liaison Psychiatry and Psychosomatic Medicine, Department of Psychiatry, Faculty of Medicine, Pontifícia Universidad Católica de Chile, Chile
| | - A Aguirre
- Section of Consultation-Liaison Psychiatry and Psychosomatic Medicine, Department of Psychiatry, Faculty of Medicine, Pontifícia Universidad Católica de Chile, Chile
| | - C Pesce
- Section of Consultation-Liaison Psychiatry and Psychosomatic Medicine, Department of Psychiatry, Faculty of Medicine, Pontifícia Universidad Católica de Chile, Chile
| | - P Sanhueza
- Section of Consultation-Liaison Psychiatry and Psychosomatic Medicine, Department of Psychiatry, Faculty of Medicine, Pontifícia Universidad Católica de Chile, Chile
| | - P Toro
- Section of Consultation-Liaison Psychiatry and Psychosomatic Medicine, Department of Psychiatry, Faculty of Medicine, Pontifícia Universidad Católica de Chile, Chile
| |
Collapse
|
10
|
Trueba-Sáiz A, Cavada C, Fernandez AM, Leon T, González DA, Fortea Ormaechea J, Lleó A, Del Ser T, Nuñez A, Torres-Aleman I. Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. Transl Psychiatry 2013; 3:e330. [PMID: 24301648 PMCID: PMC4030321 DOI: 10.1038/tp.2013.102] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Revised: 10/17/2013] [Accepted: 10/21/2013] [Indexed: 01/08/2023] Open
Abstract
Circulating insulin-like growth factor I (IGF-I) enters the brain and promotes clearance of amyloid peptides known to accumulate in Alzheimer's disease (AD) brains. Both patients and mouse models of AD show decreased level of circulating IGF-I enter the brain as evidenced by a lower ratio of cerebrospinal fluid/plasma IGF-I. Importantly, in presymptomatic AD mice this reduction is already manifested as a decreased brain input of serum IGF-I in response to environmental enrichment. To explore a potential diagnostic use of this early loss of IGF-I input, we monitored electrocorticogram (ECG) responses to systemic IGF-I in mice. Whereas control mice showed enhanced ECG activity after IGF-I, presymptomatic AD mice showed blunted ECG responses. Because nonhuman primates showed identically enhanced electroencephalogram (EEG) activity in response to systemic IGF-I, loss of the EEG signature of serum IGF-I may be exploited as a disease biomarker in AD patients.
Collapse
Affiliation(s)
- A Trueba-Sáiz
- Systems Neurobiology, Cajal Institute (CSIC), Madrid, Spain,CIBERNED, Madrid, Spain
| | - C Cavada
- Department of Neurosciences, UAM, Madrid, Spain
| | - A M Fernandez
- Systems Neurobiology, Cajal Institute (CSIC), Madrid, Spain,CIBERNED, Madrid, Spain
| | | | - D A González
- CIBERNED, Madrid, Spain,Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J Fortea Ormaechea
- CIBERNED, Madrid, Spain,Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - A Lleó
- CIBERNED, Madrid, Spain,Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - A Nuñez
- Department of Neurosciences, UAM, Madrid, Spain
| | - I Torres-Aleman
- Systems Neurobiology, Cajal Institute (CSIC), Madrid, Spain,CIBERNED, Madrid, Spain,Systems Neurobiology, Cajal Institute. Avda Dr Arce 37, Madrid 28002, Spain. E-mail:
| |
Collapse
|
11
|
Leon T, Ayala G, Gaston M, Mallor F. Using mathematical morphology for unsupervised classification of functional data. J STAT COMPUT SIM 2011. [DOI: 10.1080/00949651003596099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Leon T, Whalen E, Arnold L, Pauer L, Barrett J. Pregabalin improves pain in fibromyalgia (FM) patients regardless of baseline anxiety and depression levels. Eur Psychiatry 2008. [DOI: 10.1016/j.eurpsy.2008.01.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
13
|
Barrett J, Zeiher B, Pauer L, Leon T, Whalen E. Pregabalin as long-term treatment of fibromyalgia pain. Eur Psychiatry 2008. [DOI: 10.1016/j.eurpsy.2008.01.1265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
14
|
Bobes Garcia J, Montgomery S, Baldinetti F, Leon T, Mandel F, Pauer L, Chatamra K. Pregabalin for the treatment of generalized anxiety disorder (GAD): Efficacy and safety in elderly patients. Eur Psychiatry 2007. [DOI: 10.1016/j.eurpsy.2007.01.945] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
15
|
Leon T. Making a difference. Bringing the wellness message to teens. Concern 1996; 25:14-5. [PMID: 8715200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|